Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.29−0.21 (-0.31%)
Close on Nov 18, 2026Market cap $16.66BP/E 20.4Yield –
Exelixis operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Exelixis's operating income for the twelve months ending Oct 2, 2026 was $1.00B, up 25.4% year over year. For fiscal 2025 it was $872.19M, up 44.3% from the year before. The highest annual figure on record is $872.19M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $872.19M | +44.3% |
| FY2024 | Jan 3, 2025 | $604.62M | +253.8% |
| FY2023 | Dec 29, 2023 | $170.89M | -15.2% |
| FY2022 | Dec 30, 2022 | $201.48M | -29.7% |
| FY2021 | Dec 31, 2021 | $286.67M | +160.5% |
| FY2020 | Jan 1, 2021 | $110.06M | -70.2% |
| FY2019 | Jan 3, 2020 | $369.47M | -15.8% |
| FY2018 | Dec 28, 2018 | $438.86M | +164.5% |
| FY2017 | Dec 29, 2017 | $165.91M | – |
| FY2016 | Dec 31, 2016 | -$28.12M | – |
| FY2015 | Dec 31, 2015 | -$121.42M | – |
| FY2014 | Dec 31, 2014 | -$224.46M | – |
| FY2013 | Dec 31, 2013 | -$200.73M | – |
| FY2012 | Dec 31, 2012 | -$122.44M | -236.7% |
| FY2011 | Dec 31, 2011 | $89.54M | – |
| FY2010 | Dec 31, 2010 | -$91.40M | – |
| FY2009 | Dec 31, 2009 | -$121.91M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | $268.42M | +13.5% |
| Q2 FY2026 | Jul 3, 2026 | $248.41M | +16.3% |
| Q1 FY2026 | Apr 3, 2026 | $251.34M | +34.5% |
| Q4 FY2025 | Jan 2, 2026 | $235.22M | +44.1% |
| Q3 FY2025 | Oct 3, 2025 | $236.54M | +73.8% |
| Q2 FY2025 | Jul 4, 2025 | $213.58M | -22.6% |
| Q1 FY2025 | Apr 4, 2025 | $186.86M | +534.2% |
| Q4 FY2024 | Jan 3, 2025 | $163.21M | +99.5% |
| Q3 FY2024 | Sep 27, 2024 | $136.08M | – |
| Q2 FY2024 | Jun 28, 2024 | $275.87M | +254.4% |
| Q1 FY2024 | Mar 29, 2024 | $29.46M | +2.2% |
| Q4 FY2023 | Dec 29, 2023 | $81.79M | – |
| Q3 FY2023 | Sep 29, 2023 | -$17.58M | -121.3% |
| Q2 FY2023 | Jun 30, 2023 | $77.85M | -7.0% |
| Q1 FY2023 | Mar 31, 2023 | $28.83M | -65.4% |
| Q4 FY2022 | Dec 30, 2022 | -$48.08M | -141.2% |
| Q3 FY2022 | Sep 30, 2022 | $82.61M | +60.0% |
| Q2 FY2022 | Jul 1, 2022 | $83.71M | -32.0% |
| Q1 FY2022 | Apr 1, 2022 | $83.24M | – |
| Q4 FY2021 | Dec 31, 2021 | $116.64M | +380.1% |
| Q3 FY2021 | Oct 1, 2021 | $51.62M | – |
| Q2 FY2021 | Jul 2, 2021 | $123.01M | +62.9% |
| Q1 FY2021 | Apr 2, 2021 | -$4.61M | -108.7% |
| Q4 FY2020 | Jan 1, 2021 | $24.30M | -68.6% |
| Q3 FY2020 | Oct 2, 2020 | -$42.58M | -136.8% |
| Q2 FY2020 | Jul 3, 2020 | $75.53M | -17.9% |
| Q1 FY2020 | Apr 3, 2020 | $52.81M | -37.5% |
| Q4 FY2019 | Jan 3, 2020 | $77.32M | -30.7% |
| Q3 FY2019 | Sep 27, 2019 | $115.61M | -7.6% |
| Q2 FY2019 | Jun 28, 2019 | $91.99M | +7.3% |
| Q1 FY2019 | Mar 29, 2019 | $84.56M | -27.3% |
| Q4 FY2018 | Dec 28, 2018 | $111.60M | +198.2% |
| Q3 FY2018 | Sep 28, 2018 | $125.18M | +54.2% |
| Q2 FY2018 | Jun 29, 2018 | $85.77M | +216.3% |
| Q1 FY2018 | Mar 30, 2018 | $116.31M | +476.2% |
| Q4 FY2017 | Dec 29, 2017 | $37.43M | -3.7% |
| Q3 FY2017 | Sep 30, 2017 | $81.18M | – |
| Q2 FY2017 | Jun 30, 2017 | $27.11M | – |
| Q1 FY2017 | Mar 31, 2017 | $20.19M | – |
| Q4 FY2016 | Dec 31, 2016 | $38.88M | – |
See a number that looks wrong?